Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia
/
RSS Feed
Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071209_susan_o_brien.mp3]
You may also like...
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer 31 Aug, 2007 
Whole Brain Radiotherapy Does Not Benefit Patients with Brain Metastases from Lung Cancer—European Respiratory Society 2016 Congress 5 Sep, 2016 - Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer 18 Jul, 2018
- BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer 27 Mar, 2015
